Citron's Left reiterates belief AbbVie shares will fall sharply

Short-seller Andrew Left's Citron Research expanded on his prediction that U.S. drugmaker AbbVie Inc's stock would fall to $60 a share, arguing that new regulations to speed biosimilar drugs to the market and reform rebates will hurt revenue from the company's top-selling drug, Humira.

from Reuters: Business News https://ift.tt/2LOSTY9